ZVRA
Zevra Therapeutics Inc.
11.00$
-2.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +306.3% | +52.3% | -38.2% | -49.0% | -60.7% | +6.7% | +1,086.0% | -13.2% | +49.4% | +3.4% | +59.8% | |
| – | +426.2% | +37.5% | -38.3% | -48.3% | -70.6% | +20.2% | +1,272.7% | -19.3% | -6.4% | -1.0% | +159.2% | |
| – | +215.1% | -48.1% | -35.1% | +69.3% | -82.5% | +31.0% | +2,566.7% | -41.7% | -34.2% | -21.5% | +84.7% | |
| – | +400.4% | +32.0% | -37.7% | -48.7% | -85.2% | +31.0% | +2,566.7% | -26.3% | -18.2% | +2.6% | +174.9% | |
| – | +10,495.6% | +113.1% | -58.9% | -93.3% | +1,232.1% | +38.3% | -40.8% | +443.1% | +109.4% | -39.5% | +121.3% | |
| – | – | – | -100.0% | +22,399,900.0% | – | – | -100.0% | – | – | -91.8% | -11.7% | |
| – | – | – | – | – | – | -20.6% | -15.2% | -12.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | – | -0.3% | -90.7% | |
| – | +73.2% | +57.3% | +6.2% | -15.1% | -8.9% | -8.6% | -92.5% | +590.7% | +174.6% | +25.3% | -6.1% | |
| – | +112.0% | -20.4% | +73.3% | +4.3% | -54.8% | +38.8% | -43.9% | +184.2% | +513.2% | -53.8% | +15.3% | |
| – | +309.5% | -95.4% | +2,143.3% | +0.7% | -92.0% | +213.0% | -58.3% | +1,284.1% | +644.8% | -98.9% | -0.2% | |
| – | -20.9% | -62.5% | +364.2% | +70.6% | -69.3% | +3.0% | -56.0% | +599.8% | +287.3% | -6.5% | -81.0% | |
| – | – | – | – | – | – | -12.0% | – | – | -60.4% | +1,074.6% | +4.1% | |
| – | – | – | – | – | – | – | – | -40.9% | -17.6% | -35.9% | +289.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -40.1% | +98.1% | +0.4% | +22.4% | +65.4% | +114.8% | +647.7% | +15.9% | +2.8% | +30.5% | +23.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.